Top Medical News

New Prospective Data on Patients With Dravet Syndrome Inform Outcome Measurements in Trials

December 03, 2022

By Matt Hoffman

Data from the BUTTERFLY study of 36 children with Dravet syndrome have provided 12-month measurements of neurodevelopment, clinical status, quality of life, and executive function. Investigators expressed that these data will help inform future trial outcome measures.

The Pediatric Epilepsy Learning Healthcare System Provides Big Data to Answer Big Questions

December 03, 2022

By Isabella Ciccone, MPH

Zachary Grinspan, MD, MS, a pediatric epilepsy specialist at Weill Cornell Medicine, in New York City, spoke about the analysis of large amounts of data on pediatric epilepsy at the 2022 American Epilepsy Society Annual Meeting.

Mirtazapine and Carbamazepine Fail to Demonstrate Clinical and Cost Effectiveness as Alzheimer Agitation Treatments

December 03, 2022

By Marco Meglio

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

NeurologyLive® Friday 5 — December 2, 2022

December 02, 2022

By NeurologyLive® Staff

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 2, 2022.

Brexpiprazole Continues to Demonstrate Efficacy as Alzheimer Agitation Therapy Across Multiple Phase 3 Trials

December 02, 2022

By Marco Meglio

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Featured

Latest Videos

Insomnia Treatment Selection: DORA

S1P Receptor Modulator Treatment in Female Patients with MS

Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple Sclerosis

Interdisciplinary Care Teams in Epilepsy Care: Lucretia Long, ARPN-CNP

Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD

Understanding the Safety Profile of Lecanamab: Marwan Sabbagh, MD, FAAN

Donanemab Outperforms Aducanumab in Amyloid Clearance, FDA Grants Priority Review to SRP-9001, Atogepant Improves PROs

Shifting the Paradigm of Clinical Research in Alzheimer Disease With the COCOA Trial: Jared Roach, MD, PhD

Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH

Behavioral Lifestyle Interventions to Improve Cognitive Outcomes for Alzheimer Disease: Jared Roach, MD, PhD

The Expectations for the 2023 MDA Conference: Donald S. Wood, PhD; Sharon Hesterlee, PhD

Expanding the Biomarker Panel in MS: Jens Kuhle, MD, PhD

Dual Orexin Receptor Antagonist (DORA) for Treatment of Insomnia

Most Recent

Episode 78: A Virtual Reality Platform for Parkison Disease

December 02, 2022

Podcast

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontine in Dementia With Lewy Bodies, Parkinson Disease Dementia

December 01, 2022

Article

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Sleep and Wakefulness Pathways

December 01, 2022

Video

Wendy Wright and Debra Davis provide an overview of pathways and neurotransmitters involved in sleep and wake cycles.

Insomnia Increases Risk of Subjective Memory Decline in Middle-Aged and Older Adults

December 01, 2022

Article

Results from a longitudinal study suggest that higher proportions of subjective memory decline are associated with insomnia disorder in middle-aged and older adults.

Targeting Inflammation to Reduce Effects of Alzheimer Disease: RJ Tesi, MD

December 01, 2022

Video

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

December 01, 2022

Article

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

ACI-35.030 and JACI-35.054 Vaccinations Demonstrate Safety in Early Alzheimer Disease

November 30, 2022

Article

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

Longitudinal Study to Investigate Health and Lifestyle Behavior Effects on MS: Michelle Chen, PhD

November 30, 2022

Video

The neuropsychologist at Rutgers University spoke about her recently awarded NIH grant to study the impact of health and lifestyle behaviors in individuals with MS. [WATCH TIME: 3 minutes]

Duchenne Gene Therapy SRP-9001 Wins Priority Review

November 30, 2022

Article

The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.

Music-Based Application to Improve Insomnia in Patients With Dementia and Their Caregivers: Darina Petrovsky, PhD, RN

November 30, 2022

Video

The assistant professor, Rutgers University, New Brunswick, New Jersey, offers an overview on her ongoing lab project about a music-based intervention to improve insomnia in dementia and caregivers. [WATCH TIME: 3 minutes]

Latest SAP Content

Interdisciplinary Care Teams in Epilepsy Care: Lucretia Long, ARPN-CNP

Using Semiology to Improve Epilepsy Clinical Trials: Jacqueline French, MD

Addressing Unmet Needs of Dementia With Lewy Bodies: James Galvin, MD, MPH

Episode 78: A Virtual Reality Platform for Parkison Disease

View More SAP Content